Des scientifiques d'Abou Dhabi offrent un nouvel espoir aux personnes atteintes de la maladie de Huntington

Abu Dhabi scientists have made a breakthrough in the search for a treatment for Huntington's disease, offering new hope to millions affected by the condition worldwide. Researchers at the Abu Dhabi Stem Cells Centre (ADSCC) claim they have identified a method that could slow the progression of the disease by targeting its underlying mechanisms. Their findings suggest that focusing on astrocytes, supportive brain cells rather than the neurons traditionally studied, has revealed promising avenues for intervention. The discovery emerged from experiments involving patient-derived stem cells, which were transformed into brain tissue in a controlled environment. Scientists observed that the mutant huntingtin protein, responsible for the disease, disrupts key molecular pathways essential for maintaining the structural integrity of astrocytes. This disruption impairs the cells' ability to support neurons, contributing to the progressive loss of brain function characteristic of Huntington's. By identifying these disruptions, the team was able to test three drugs that corrected the affected pathways, showing immediate positive effects in laboratory conditions. In addition to lab-based studies, the researchers conducted tests on genetically modified fruit flies, which carry the Huntington’s mutation. Flies not treated with the drugs exhibited severe motor impairments and shortened lifespans, whereas those receiving the treatment regained mobility and extended their lifespan. These results provide compelling evidence that the approach could translate effectively to humans. One of the compounds tested is currently undergoing phase III clinical trials for a different illness, indicating that it has already undergone extensive safety assessments. Prof Angelo L Vescovi, the lead researcher, emphasized that this method differs from existing approaches. While other teams focus on reducing the production of the faulty huntingtin protein, the ADSCC team targets the consequences of this mutation. "We act further downstream," he explained, highlighting that their strategy addresses the functional decline caused by the defective protein rather than attempting to halt its creation outright. This shift in focus reflects a broader trend in Huntington’s research. In recent years, advancements such as gene therapy have shown promise. Last year, a trial at University College London demonstrated that reducing huntingtin protein levels can slow disease progression in early-stage patients. Despite these developments, clinical trials have often faced setbacks due to the complexity of the disorder, which affects multiple cellular processes simultaneously. The ADSCC team aims to advance their findings toward human trials within two years, contingent upon securing sufficient funding. Their work involves laboratory-grown brain tissues from six individuals diagnosed with Huntington’s, ranging in age from nine to 63. The diversity of participants adds depth to the study, allowing researchers to examine how the disease manifests across different stages of life. While the path to human application remains uncertain, the preliminary success of the ADSCC project marks a significant step forward. As global efforts continue to unravel the mysteries of Huntington’s disease, innovations like these offer renewed optimism for future therapeutic options.